Shield Therapeutics (STX) RNS Announcements

Add to Alert list
Date Time Source Announcement
23 Jan 2019 10:19 AM
RNS
Investor presentations
22 Jan 2019 07:00 AM
RNS
Appointment of Chairman
13 Dec 2018 07:00 AM
RNS
US New Drug Application PDUFA date for Feraccru
05 Dec 2018 10:04 AM
RNS
UK launch of Feraccru® by Norgine
03 Dec 2018 07:00 AM
RNS
New Drug Application for Feraccru®
09 Nov 2018 03:46 PM
RNS
Holding(s) in Company
08 Nov 2018 06:21 PM
RNS
Holding(s) in Company
01 Oct 2018 01:54 PM
RNS
Notification Of Major Holdings
01 Oct 2018 07:00 AM
RNS
Submission of an NDA for Feraccru® with the FDA
24 Sep 2018 01:06 PM
RNS
Director/PDMR Shareholding
24 Sep 2018 01:02 PM
RNS
Holding(s) in Company
19 Sep 2018 07:14 AM
RNS
Licence for the commercialisation of Feraccru
19 Sep 2018 07:12 AM
RNS
Interim Results
13 Sep 2018 07:00 AM
RNS
AEGIS-H2H Completion of Recruitment
26 Jul 2018 07:00 AM
RNS
Appointment of Non-Executive Director
23 Jul 2018 07:00 AM
RNS
Business Update
09 Jul 2018 04:27 PM
RNS
Holdings in Company
09 Jul 2018 04:26 PM
RNS
Holdings in Company
28 Jun 2018 11:56 AM
RNS
Result of AGM
28 Jun 2018 07:00 AM
RNS
Data from real-world clinical use of Feraccru
14 Jun 2018 07:00 AM
RNS
Positive top-line results from AEGIS-PAED PK study
05 Jun 2018 07:00 AM
RNS
Directorate Change
05 Jun 2018 07:00 AM
RNS
2017 Annual Report and 2018 AGM Notice
15 May 2018 06:21 PM
RNS
Grant of share options
04 May 2018 09:20 AM
RNS
Holding(s) in Company
03 May 2018 05:26 PM
RNS
Holding(s) in Company
02 May 2018 11:00 AM
RNS
Price Monitoring Extension
11 Apr 2018 07:00 AM
RNS
Preliminary Results for the Year Ended 31 Dec 17
06 Apr 2018 07:00 AM
RNS
Appointment of Non-Executive Director
06 Apr 2018 07:00 AM
RNS
Results of Pre-Submission Meeting with FDA
27 Mar 2018 07:00 AM
RNS
Broadening of Feraccru indication
16 Mar 2018 07:00 AM
RNS
Update on the AEGIS-CKD study
23 Feb 2018 01:56 PM
RNS
Receives CHMP positive opinion on Feraccru®
22 Feb 2018 07:00 AM
RNS
Business and Trading Update
05 Feb 2018 07:00 AM
RNS
Top-line results from Feraccru Phase III study
29 Jan 2018 07:00 AM
RNS
Notice of Results
25 Jan 2018 07:00 AM
RNS
Grant of share options
10 Oct 2017 07:00 AM
RNS
Completion of patient enrolment in Phase 3 study
05 Oct 2017 07:00 AM
RNS
PDMR Acquisition of Shares
20 Sep 2017 07:00 AM
RNS
Interim Report
14 Sep 2017 07:00 AM
RNS
Board Change
06 Sep 2017 07:00 AM
RNS
US Composition of Matter Patent Allowed
31 Aug 2017 07:00 AM
RNS
Shield to Present at Baird Healthcare Conference
15 Aug 2017 07:00 AM
RNS
Notice of Results
11 Jul 2017 02:59 PM
RNS
Grant of Share Options
10 Jul 2017 04:16 PM
RNS
Holding(s) in Company
06 Jul 2017 07:00 AM
RNS
Feraccru licence agreement for Switzerland
05 Jul 2017 12:38 PM
RNS
Holding(s) in Company
03 Jul 2017 12:34 PM
RNS
Warrant Exercise and Expiry
28 Jun 2017 10:37 AM
RNS
Holding(s) in Company

Shield Therapeutics is a pharmaceutical company that develops medicines to treat iron deficiency.

Shield Therapeutics share price is listed on LSE under the ticker STX.

UK 100

Latest directors dealings